{"protocolSection": {"identificationModule": {"nctId": "NCT00886600", "orgStudyIdInfo": {"id": "0954-021"}, "secondaryIdInfos": [{"id": "MK0954-021"}, {"id": "2009_581"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)", "officialTitle": "A Double-blind, Randomized, Parallel-group, Placebo-controlled Pilot Study to Investigate the Magnitude and Duration of Response and the Safety of MK0954 (50 mg Given Once or Twice Daily, or 100 mg Given Once Daily) Compared to Placebo Using Ambulatory Blood Pressure Monitoring"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1991-05"}, "primaryCompletionDateStruct": {"date": "1992-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "1992-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-22", "studyFirstSubmitQcDate": "2009-04-22", "studyFirstPostDateStruct": {"date": "2009-04-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-21", "resultsFirstSubmitQcDate": "2009-05-21", "resultsFirstPostDateStruct": {"date": "2009-07-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-17", "lastUpdatePostDateStruct": {"date": "2015-08-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (ABPM), and to evaluate the safety of losartan 50 and 100 mg doses compared to placebo."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 122, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Comparator: placebo", "Drug: hydrochlorothiazide (HCTZ)"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "losartan 50 mg q.d.", "interventionNames": ["Drug: losartan potassium", "Drug: hydrochlorothiazide (HCTZ)"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "losartan 100 mg q.d.", "interventionNames": ["Drug: losartan potassium", "Drug: hydrochlorothiazide (HCTZ)"]}, {"label": "4", "type": "EXPERIMENTAL", "description": "losartan 50 mg b.i.d.", "interventionNames": ["Drug: losartan potassium", "Drug: hydrochlorothiazide (HCTZ)"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium", "description": "losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks", "armGroupLabels": ["2", "3", "4"], "otherNames": ["MK0954"]}, {"type": "DRUG", "name": "Comparator: placebo", "description": "placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "hydrochlorothiazide (HCTZ)", "description": "open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) \u226585 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks", "armGroupLabels": ["1", "2", "3", "4"], "otherNames": ["HCTZ"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4", "timeFrame": "24 hour period at Baseline and Week 4"}, {"measure": "Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4", "timeFrame": "24-hour period at baseline and Week 4"}], "secondaryOutcomes": [{"measure": "Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4", "timeFrame": "Baseline and 24-hours after morning dose at Week 4"}, {"measure": "Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6", "timeFrame": "Baseline and 24-hours after morning dose at Week 6"}, {"measure": "Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6", "timeFrame": "Baseline and 24-hours after morning dose at Week 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Non-black men and women with mild to moderate hypertension and within 30% of their ideal body weight\n* Patient is in good general health\n* Blood pressure at time of randomization is 95-115 mm Hg\n\nExclusion Criteria:\n\n* Secondary Hypertension or history of malignant hypertension\n* History of stroke\n* History of myocardial infarction\n* Atrial flutter or atrial fibrillation\n* History of congestive Heart failure\n* Patient taking major psychotropic agent or anti-depressant\n* Patient regularly uses NSAIDS or high dose aspirin\n* Known positive test for HIV/AIDS or Hepatitis B\n* Patient is being treated for acute ulcer disease\n* Prior exposure to losartan\n* Actively treated diabetes mellitus\n* History of chronic liver disease\n* Actively treated diabetes mellitus\n* Any known bleeding or platelet disorder\n* Absence of one kidney\n* Women of childbearing potential\n* Alcoholism or drug addiction", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "7848024", "type": "BACKGROUND", "citation": "Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995 Feb 27;155(4):405-11. Erratum In: Arch Intern Med 1995 Apr 24;155(8):876."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients could be randomized if sitting diastolic blood pressure (SiDBP) after 2 and 4 weeks of placebo washout was 95-115 mm Hg and the difference between measurements at the 2 visits was \u22647 mm Hg. At the end of placebo baseline the mean 24-hr DBP using ambulatory blood pressure monitoring (ABPM) had to be at least 85 mm Hg.", "recruitmentDetails": "Patients were recruited at 9 sites in the United States. Prime Therapy Period: May, 1991 to March, 1992.", "groups": [{"id": "FG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Double-blind Monotherapy: Losartan placebo orally once daily for 4 weeks\n\nCombination Therapy Period: Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg after 4 weeks of losartan monotherapy) orally once daily for 2 weeks"}, {"id": "FG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Double-blind Monotherapy: Losartan 50 mg orally once daily (q.d.) for 4 weeks\n\nCombination Therapy Period: Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg after 4 weeks of losartan monotherapy) orally once daily for 2 weeks"}, {"id": "FG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Double-blind Monotherapy: Losartan 100 mg orally once daily (q.d.) for 4 weeks\n\nCombination Therapy Period:Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg after 4 weeks of losartan monotherapy).orally once daily for 2 weeks"}, {"id": "FG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Double-blind Monotherapy: Losartan 50 mg orally twice daily (b.i.d.) for 4 weeks\n\nCombination Therapy Period: Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg after 4 weeks of losartan monotherapy) orally once daily for 2 weeks"}], "periods": [{"title": "Double-blind Monotherapy", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "29"}, {"groupId": "FG002", "numSubjects": "30"}, {"groupId": "FG003", "numSubjects": "31"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "comment": "1 pt discontinued after Wk 4 due to AE starting in placebo baseline and continuing into double-blind", "numSubjects": "28"}, {"groupId": "FG002", "numSubjects": "29"}, {"groupId": "FG003", "numSubjects": "29"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Combination Therapy Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Patients did not continue from monotherapy period : 2-(Sitting Diastolic Blood Pressure (SiDBP) \\<85)", "numSubjects": "28"}, {"groupId": "FG001", "comment": "Patients did not continue from monotherapy period : 4-(SiDBP \\<85); 3-(SiDBP \u226585)", "numSubjects": "21"}, {"groupId": "FG002", "comment": "Patients did not continue from monotherapy period : 7-(SiDBP \\<85); 1-(SiDBP \u226585)", "numSubjects": "21"}, {"groupId": "FG003", "comment": "Patients did not continue from monotherapy period : 5-(SiDBP \\<85); 1-(SiDBP \u226585)", "numSubjects": "23"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "19"}, {"groupId": "FG003", "numSubjects": "23"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Losartan placebo orally once daily for 4 weeks followed by Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "BG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally once daily for 4 weeks followed by Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "BG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 100 mg orally once daily for 4 weeks followed by Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg).orally once daily for 2 weeks"}, {"id": "BG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally twice daily for 4 weeks followed by Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "31"}, {"groupId": "BG004", "value": "122"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.2", "spread": "12.0"}, {"groupId": "BG001", "value": "56.8", "spread": "12.1"}, {"groupId": "BG002", "value": "51.2", "spread": "9.6"}, {"groupId": "BG003", "value": "54.1", "spread": "9.0"}, {"groupId": "BG004", "value": "53.5", "spread": "10.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "13"}, {"groupId": "BG004", "value": "39"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "18"}, {"groupId": "BG004", "value": "83"}]}]}]}, {"title": "Race/Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "30"}, {"groupId": "BG003", "value": "30"}, {"groupId": "BG004", "value": "119"}]}]}, {"title": "Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "1"}]}]}, {"title": "Filipino", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}, {"title": "Indian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}]}, {"title": "Diastolic 24-hr mean ambulatory blood pressure monitoring (ABPM)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "94.8", "spread": "5.9"}, {"groupId": "BG001", "value": "94.0", "spread": "6.9"}, {"groupId": "BG002", "value": "93.8", "spread": "6.0"}, {"groupId": "BG003", "value": "94.4", "spread": "6.9"}, {"groupId": "BG004", "value": "94.2", "spread": "6.4"}]}]}]}, {"title": "Sitting Diastolic Blood Pressure (SiDBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "100.7", "spread": "4.0"}, {"groupId": "BG001", "value": "100.0", "spread": "4.6"}, {"groupId": "BG002", "value": "101.5", "spread": "5.1"}, {"groupId": "BG003", "value": "101.2", "spread": "4.8"}, {"groupId": "BG004", "value": "100.9", "spread": "4.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4", "populationDescription": "The efficacy analysis followed a \"per protocol\" approach in that only patients who completed the study according to the protocol were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "24 hour period at Baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Losartan placebo orally once daily for 4 weeks followed by Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally once daily for 4 weeks followed by Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 100 mg orally once daily for 4 weeks followed by Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg).orally once daily for 2 weeks"}, {"id": "OG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally twice daily for 4 weeks followed by Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "4.8"}, {"groupId": "OG001", "value": "-5.2", "spread": "5.1"}, {"groupId": "OG002", "value": "-6.4", "spread": "5.5"}, {"groupId": "OG003", "value": "-8.5", "spread": "6.7"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4", "populationDescription": "The efficacy analysis followed a \"per protocol\" approach in that only patients who completed the study according to the protocol were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "24-hour period at baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Losartan placebo orally once daily for 4 weeks followed by Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally once daily for 4 weeks followed by Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 100 mg orally once daily for 4 weeks followed by Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg).orally once daily for 2 weeks"}, {"id": "OG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally twice daily for 4 weeks followed by Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "7.8"}, {"groupId": "OG001", "value": "-9.2", "spread": "9.9"}, {"groupId": "OG002", "value": "-9.9", "spread": "7.6"}, {"groupId": "OG003", "value": "-13.2", "spread": "10.6"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4", "populationDescription": "The efficacy analysis followed a \"per protocol\" approach in that only patients who completed the study according to the protocol were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 24-hours after morning dose at Week 4", "groups": [{"id": "OG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Losartan placebo orally once daily for 4 weeks followed by Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally once daily for 4 weeks followed by Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 100 mg orally once daily for 4 weeks followed by Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg).orally once daily for 2 weeks"}, {"id": "OG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally twice daily for 4 weeks followed by Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "6.9"}, {"groupId": "OG001", "value": "-6.7", "spread": "7.8"}, {"groupId": "OG002", "value": "-9.6", "spread": "6.5"}, {"groupId": "OG003", "value": "-8.8", "spread": "7.8"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6", "populationDescription": "The efficacy analysis followed a \"per protocol\" approach in that only patients who completed the study according to the protocol were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 24-hours after morning dose at Week 6", "groups": [{"id": "OG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Losartan placebo orally once daily for 4 weeks followed by Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally once daily for 4 weeks followed by Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 100 mg orally once daily for 4 weeks followed by Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg).orally once daily for 2 weeks"}, {"id": "OG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally twice daily for 4 weeks followed by Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "6.1"}, {"groupId": "OG001", "value": "-9.9", "spread": "6.3"}, {"groupId": "OG002", "value": "-10.7", "spread": "4.9"}, {"groupId": "OG003", "value": "-10.1", "spread": "7.8"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6", "populationDescription": "The efficacy analysis followed a \"per protocol\" approach in that only patients who completed the study according to the protocol were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 24-hours after morning dose at Week 6", "groups": [{"id": "OG000", "title": "Placebo / HCTZ 12.5 mg", "description": "Losartan placebo orally once daily for 4 weeks followed by Losartan placebo + open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG001", "title": "Losartan 50 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally once daily for 4 weeks followed by Losartan 50 mg + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}, {"id": "OG002", "title": "Losartan 100 mg q.d. / HCTZ 12.5 mg", "description": "Losartan 100 mg orally once daily for 4 weeks followed by Losartan 100 mg once daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg).orally once daily for 2 weeks"}, {"id": "OG003", "title": "Losartan 50 mg b.i.d. / HCTZ 12.5 mg", "description": "Losartan 50 mg orally twice daily for 4 weeks followed by Losartan 50 mg twice daily + open-label HCTZ 12.5 mg (for patients with SiDBP \u226585 mm Hg) orally once daily for 2 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.0", "spread": "6.4"}, {"groupId": "OG001", "value": "-5.1", "spread": "7.8"}, {"groupId": "OG002", "value": "-4.0", "spread": "6.1"}, {"groupId": "OG003", "value": "-4.0", "spread": "6.9"}]}]}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Safety has been reported in the literature."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Executive Vice President, Clinical and Quantitative Sciences", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}], "browseLeaves": [{"id": "M21701", "name": "Losartan", "asFound": "Gradual", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}